Medicenna Presents Preclinical Results from its IL-2 Super-Antagonist and Anti-PD1-IL-2 BiSKIT Programs at The Promise of Interleukin-2 Therapy Conference
September 09, 2024 07:32 ET
|
Medicenna Therapeutics Corp.
MDNA209 is a first-in-class “beta-enhanced” IL-2 Super-antagonist being developed for the potential treatment of autoimmune diseases, a disorder attributed to an imbalance of the immune system and...
Medicenna to Participate at the H.C. Wainwright 26th Annual Global Investment Conference
September 05, 2024 07:00 ET
|
Medicenna Therapeutics Corp.
TORONTO and HOUSTON, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company...
Medicenna Announces Upcoming Presentations at The Promise of Interleukin-2 Therapy Conference
August 27, 2024 07:00 ET
|
Medicenna Therapeutics Corp.
TORONTO and HOUSTON, Aug. 27, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company focused...
Medicenna Strengthens Board of Directors with Appointment of Karim Lalji
August 15, 2024 07:30 ET
|
Medicenna Therapeutics Corp.
TORONTO and HOUSTON, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company focused on the...
Medicenna Reports First Quarter Fiscal 2025 Financial Results and Announces First Complete Responder with MDNA11 Monotherapy
August 01, 2024 07:00 ET
|
Medicenna Therapeutics Corp.
Patient with melanoma, having failed dual check-point inhibitor therapy, achieved a complete response following treatment with MDNA11 at week 52 with 100% regression of all target and non-target...
Medicenna Therapeutics Reports Fiscal Year 2024 Financial Results and Operational Highlights
June 27, 2024 08:18 ET
|
Medicenna Therapeutics Corp.
Increased cash balance to $37 million following a $20 million investment by RA Capital extending runway into mid-2026 MDNA11 continues to exhibit compelling deep and durable single agent activity and...
Medicenna Announces EMA Approval of its Clinical Trial Application to Expand its Phase 1/2 ABILITY-1 Study to Europe
June 26, 2024 07:47 ET
|
Medicenna Therapeutics Corp.
- ABILITY-1 study is currently enrolling patients for the treatment of advanced solid tumors with MDNA11, a novel long-acting IL-2 super-agonist, as a monotherapy or in combination with KEYTRUDA®, at...
Medicenna Reports Significant Survival Benefit in Patients with Recurrent Glioblastoma Following Treatment with Bizaxofusp When Compared to a Matched External Control Arm at the 2024 ASCO Annual Meeting
June 03, 2024 08:00 ET
|
Medicenna Therapeutics Corp.
Single treatment with bizaxofusp achieved significant survival benefit (mOS of 13.5 vs. 7.2 months, p=0.009) and reduced risk of death by almost half (hazard ratio: 0.54, 95% confidence interval:...
Medicenna To Present Evidence of Durable Single Agent Activity and Potent Immune Effector Response with MDNA11 in the Dose Escalation Portion of Phase 1/2 ABILITY-1 Study at the 10th Annual Oncology Innovation Forum
May 31, 2024 09:29 ET
|
Medicenna Therapeutics Corp.
MDNA11 demonstrates durable response in pancreatic cancer patient with 100% regression of target and non-target lesions for over 104 weeks and continues to show remission 4 months after stopping...
Medicenna to Present Clinical Update on the MDNA11 ABILITY-1 Trial at the Upcoming Sachs 10th Annual Oncology Innovation Forum
May 22, 2024 07:00 ET
|
Medicenna Therapeutics Corp.
TORONTO and HOUSTON, May 22, 2024 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (TSX: MDNA, OTCQB: MDNAF), a clinical-stage immunotherapy company focused...